Literature DB >> 28135008

Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.

Safieh Ebrahimi1, Elnaz Ghorbani2, Majid Khazaei3, Amir Avan4,5, Mikhail Ryzhikov6, Kayhan Azadmanesh7, Seyed Mahdi Hassanian1,4,8.   

Abstract

Interferons (INFs) elicit antiviral responses in tumor cells upon binding to cell surface receptors. Oncolytic virotherapy (OV) is an effective antitumor therapeutic approach which in combination with standard radiotherapy or chemotherapy regimens potentiates treatment responses in cancer patients. However, oncolytic viruses are susceptible to the IFN-induced antiviral state in the tumor microenvironment. A number of studies have, therefore, investigated the effects of combined therapy of IFN signaling pharmacological inhibitors with oncolytic viruses, which result in improved virus replication and oncolysis. This review summarizes the current knowledge of the mechanisms of interferon-mediated tumor resistance to oncolytic virotherapy and provides new insights regarding the effectiveness of combinatorial treatment strategies to attenuate INF-induced OV resistance for greater clinical significance in the treatment of cancer patients. J. Cell. Biochem. 118: 1994-1999, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CANCER; INTERFERON; ONCOLYTIC VIROTHERAPY

Mesh:

Substances:

Year:  2017        PMID: 28135008     DOI: 10.1002/jcb.25917

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Reovirus μ2 protein modulates host cell alternative splicing by reducing protein levels of U5 snRNP core components.

Authors:  Simon Boudreault; Mathieu Durand; Carole-Anne Martineau; Jean-Pierre Perreault; Guy Lemay; Martin Bisaillon
Journal:  Nucleic Acids Res       Date:  2022-05-20       Impact factor: 19.160

2.  Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.

Authors:  Dobrin D Draganov; Antonio F Santidrian; Ivelina Minev; Duong Nguyen; Mehmet Okyay Kilinc; Ivan Petrov; Anna Vyalkova; Elliot Lander; Mark Berman; Boris Minev; Aladar A Szalay
Journal:  J Transl Med       Date:  2019-03-27       Impact factor: 5.531

3.  Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance.

Authors:  Weike Li; Ravi Chakra Turaga; Xin Li; Malvika Sharma; Zahra Enadi; Sydney Nicole Dunham Tompkins; Kyle Christian Hardy; Falguni Mishra; Jun Tsao; Zhi-Ren Liu; Daping Fan; Ming Luo
Journal:  Mol Ther Oncolytics       Date:  2019-06-04       Impact factor: 7.200

4.  IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity.

Authors:  Nader El-Sayes; Scott Walsh; Alyssa Vito; Amir Reihani; Kjetil Ask; Yonghong Wan; Karen Mossman
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 7.200

Review 5.  Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.

Authors:  Amirhossein Mardi; Anastasia V Shirokova; Rebar N Mohammed; Ali Keshavarz; Angelina O Zekiy; Lakshmi Thangavelu; Talar Ahmad Merza Mohamad; Faroogh Marofi; Navid Shomali; Amir Zamani; Morteza Akbari
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

6.  Assessing the oncolytic potential of rotavirus on mouse myeloma cell line Sp2/0-Ag14.

Authors:  Rafael A Guerrero; Carlos A Guerrero; Fanny Guzmán; Orlando Acosta
Journal:  Biomedica       Date:  2020-06-15       Impact factor: 0.935

7.  Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors.

Authors:  Yu-Chao Zhu; Hany M Elsheikha; Jian-Hua Wang; Shuai Fang; Jun-Jun He; Xing-Quan Zhu; Jia Chen
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.